NCT03135171View on ClinicalTrials.gov

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 26, 2017

Primary Completion Date

March 16, 2020

Study Completion Date

March 20, 2020

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab

All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.

DRUG

Pertuzumab

Dose Levels two and three will receive 840 mg loading dose for cycle 1, followed by 420 mg in subsequent cycles, every 3 weeks.

DRUG

Tocilizumab

Tocilizumab 4-8 mg/kg, administered intravenously every three weeks

Trial Locations (3)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

60637

University of Chicago, Chicago

06520

Yale University, New Haven

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT03135171 - Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab | Biotech Hunter | Biotech Hunter